News For BAX From The Last 14 Days Check below for free stories on BAX the last two weeks.
There are 9 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 3, 2012
|
| 07:39 EDT |  | BAX |
|
|
January 30, 2012
|
| 09:02 EDT |  | BAX |
|
|
January 26, 2012
|
| 07:08 EDT |  | BAX |
| | 07:06 EDT | | BAX |
| theflyonthewall.com: | Baxter sees Q1 EPS ex-items 98c-$1.00 vs. consensus $1.05 | | For Q1, Baxter expects sales growth of approximately 2%, excluding the impact of foreign currency. Including the impact of foreign exchange, sales are expected to be comparable to the level achieved i Q1 of 2011. :theflyonthewall.com |
| | 07:05 EDT | | BAX |
|
|
January 25, 2012
|
| 14:54 EDT | | BAX |
|
|
January 24, 2012
|
| 11:19 EDT |  | BAX |
| theflyonthewall.com: | Dougherty recommends takting Baxter profits | | Dougherty is cautious ahead of Baxter's Q4 report on January 26 and believes the company could provide lower than expected 2012 guidance. The firm recommends taking profits following last nights favorable DSMD interim review. :theflyonthewall.com |
| | 07:57 EDT | | BAX |
| theflyonthewall.com: | Baxter shares should be bought at current levels, says RBC Capital | | RBC Capital believes that the initiation of a second Phase III clinical trial of Baxter's Alzheimer’s.treatment will be a positive catalyst for the stock. The firm thinks the treatment has a risk adjusted value of $3.50+ per share and maintains an Outperform rating on the stock. :theflyonthewall.com |
|
|
January 23, 2012
|
| 17:43 EDT | | BAX |
| theflyonthewall.com: | Baxter to intiate second Phase III trial studying Gammagard Liquid | | Baxter provided an update on its clinical program evaluating the use of its Gammagard Liquid, marketed as KIOVIG outside the United States and Canada, for the treatment of mild to moderate Alzheimer's disease. The company plans to initiate a second, confirmatory Phase III trial in the first quarter of 2012, having satisfactorily completed a futility analysis in its first Phase III trial. :theflyonthewall.com |
|
|
|
Subscribe for More Information